Preparation and application of peptide and radionuclide labeled molecular probes targeting brain glioma
By designing the polypeptide ligand HSVPRHEV and radionuclide-labeled molecular probe 99mTcO-DTPA-HSV that binds to ANGPT2 protein, the problem of targeted diagnosis and treatment in brain glioma treatment is solved, and high efficiency is achieved for brain glioma Targeted therapy and imaging significantly improve the therapeutic effect.
Patent Information
- Application Number
- CN202311272086.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-09-28
AI Technical Summary
The prior art lacks effective targeted diagnosis and treatment methods in the treatment of brain gliomas, and traditional treatment methods have limitations, and the high expression of ANGPT2 does not have high affinity polypeptide ligands in brain gliomas, which affects the therapeutic effect.
Design and synthesize the polypeptide ligand HSVPRHEV with the best binding mode and affinity with ANGPT2 protein, and prepare the radionuclide-labeled molecular probe 99mTcO-DTPA-HSV targeting ANGPT2 protein for targeted diagnosis and treatment of brain gliomas .
Targeted treatment and diagnosis of brain gliomas is achieved, with long imaging time and easy preparation, filling the gap in ANGPT2 high-affinity polypeptide ligands, and significantly improving the diagnosis and treatment effect of brain gliomas.
Smart Images

Figure CN117327148B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of new biomedical technology applications, and specifically relates to the preparation and application of a polypeptide targeting brain glioma and a radionuclide labeled molecular probe. Background Art
[0002] Gliomas are malignant primary brain tumors. The World Health Organization (WHO) classifies them into grades I to IV according to their histology. Glioblastoma multiforme (GBM), which accounts for the highest proportion of grade IV, is the most serious. The median survival of GBM patients is only 12 months, and the recurrence rate and mortality rate are extremely high, with a very poor prognosis. At present, the treatment of GBM mainly includes surgical resection and radiotherapy and chemotherapy, but these methods have certain limitations. Since GBM is a diffuse brain glioma, it is difficult to achieve complete resection by surgery, and traditional radiotherapy and chemotherapy methods also have significant toxic side effects. Therefore, more effective treatment methods are needed. At present, tumor targeted therapy technology has attracted much attention and has great potential for clinical application, but the number of targeted drugs for gliomas used in clinical practice is limited. Therefore, the development of targeted diagnostic and therapeutic drugs for GBM is of great significance to improving the survival rate of GMB patients, and it is also a hot spot and difficulty in current research in this field.
[0003] The role of angiopoietin 2 (ANGPT2) in tumor-induced angiogenesis has been gradually revealed. Inhibition of ANGPT2 expression can reduce tumor volume and inhibit tumor cell metastasis. Therefore, inhibition of ANGPT2 expression has great clinical application prospects in tumor treatment. Based on the TCGA dataset and immunohistochemical analysis, it was found that ANGPT2 is highly expressed in brain glioma tissues and is positively correlated with the stage and progression of brain gliomas. It is an oncogene of brain gliomas and has application potential in the targeted treatment of brain gliomas. Peptides are an important class of targeting ligand molecules with the characteristics of easy modification and optimization, stable chemical properties, etc. They are important ligand molecules for the development of brain glioma diagnosis and treatment drugs. At present, targeted peptides such as RGD have been used in brain glioma diagnosis. Therefore, the development of targeted peptides for ANGPT2 and their application in the diagnosis and treatment of brain gliomas has important clinical practical value. Summary of the invention
[0004] Based on the above background, one of the purposes of the present invention is to design and synthesize a polypeptide ligand with the best binding mode and affinity to the AGNPT2 protein, and ultimately obtain a polypeptide sequence targeting the AGNPT2 protein.
[0005] The polypeptide targeting AGNPT2 protein provided by the present invention has an amino acid sequence as follows: HSVPRHEV (Histidine-Serine-Valine-Proline-Arginine-Histidine-Glutamic Acid-Valine, His-Ser-Val-Pro-Arg-His-Glu-Val), abbreviated as HSV.
[0006] The present invention designs a polypeptide ligand with the best binding mode and affinity to the AGNPT2 protein, and identifies the affinity of the polypeptide to the AGNPT2 protein.
[0007] In an embodiment of the present invention, when the present invention identifies the affinity between the polypeptide HSVPRHEV and the AGNPT2 protein, the affinity identification method used is the biomembrane interferometry technology, that is, 20 μg / mL of AGNPT2 protein is immobilized on the NTA chip, 200 μL of the polypeptide HSVPRHEV with a concentration of 100 μM is added, and the affinity identification result of HSV and AGNPT2 is obtained by biomembrane interferometry analysis.
[0008] The use of the above polypeptide HSV in the preparation of drugs for diagnosing and treating brain glioma also falls within the protection scope of the present invention.
[0009] The second object of the present invention is to provide a radionuclide-labeled molecular probe based on the above-mentioned polypeptide HSV that specifically targets brain glioma.
[0010] The brain glioma may specifically be glioblastoma multiforme.
[0011] The present invention designs and synthesizes a radionuclide-labeled molecular probe with specific targeting to human brain glioma cell transplants, and explores the cell experiment and radionuclide 99m The results of TcO-labeled HSV targeting U87-MG cell transplants showed that HSV has a targeting effect on gliomas and has potential application value in imaging gliomas.
[0012] The radionuclide labeled molecular probe provided by the present invention is composed of the following components: a polypeptide HSV targeting the AGNPT2 protein, a chelating agent DTPA and a radionuclide 99m TcO, in which the peptide HSV targeting the AGNPT2 protein is covalently coupled to the chelator DTPA, a radionuclide 99m TcO is chelated to the chelating agent DTPA.
[0013] The structural formula of the chelating agent DTPA is as follows:
[0014]
[0015] The radionuclide labeled molecular probe is represented by:99m TcO-DTPA-HSV, where 99m TcO is a radionuclide, DTPA is a chelating agent, and HSV is a peptide targeting ANGPT2 protein.
[0016] Another object of the present invention is to provide a method for preparing the above-mentioned radionuclide labeled molecular probe.
[0017] The above-mentioned radionuclide labeled molecular probe is prepared by a method comprising the following steps:
[0018] 1) Preparation of Chelating Agent-Peptide
[0019] The polypeptide HSV is reacted with DTPA-tetra (t-Bu ester) to obtain the chelating agent-polypeptide DTPA-HSV;
[0020] 2) Preparation of radionuclide labeled chelator-peptide
[0021] Add radioactive nuclide to the mixed solution of chelating agent-peptide DTPA-HSV, stannous chloride and buffer 99m TcO, the reaction obtains a radionuclide labeled chelator-peptide, i.e., a radionuclide labeled molecular probe 99m TcO-DTPA-HSV.
[0022] In step 1) of the above method, the molar ratio of polypeptide HSV to DTPA-tetra (t-Bu ester) can be 1:2-3, specifically 1:3.
[0023] In step 2) of the above method, the buffer solution is 0.1M PBS buffer or physiological saline, with a pH of 7.4.
[0024] The chelating agent-polypeptide DTPA-HSV and stannous chloride, radionuclide 99m The ratio of TcO can be: 0.1-0.3mg: 0.1mg: 2.5mCi;
[0025] The reaction temperature may be room temperature, and the reaction time may be 15-30 min, specifically 30 min.
[0026] Specifically, the operation of step 2) of the above method is:
[0027] The chelating agent-peptide DTPA-HSV was dissolved in ultrapure water to a final concentration of 1 mg / mL. 300 μL of DTPA-HSV solution and 100 μL of 1 mg / mL stannous chloride solution were mixed in 500 μL of PBS and 2.5 mCi 99m T8h ,The radionuclide labeled molecular probe was prepared by reacting at room temperature for 30 minutes. 99m Tc-DTPA-HSV.
[0028] The use of the above-mentioned radionuclide labeled molecular probe in the preparation of diagnostic reagents for brain glioma also falls within the protection scope of the present invention.
[0029] In the application, the brain glioma is specifically glioblastoma multiforme.
[0030] The diagnostic reagent is used for imaging human brain glioma cells and brain glioma transplanted tumors in vivo.
[0031] According to the embodiment of the present invention, the selected human brain glioma cells are U87-MG cells, and the selected in vivo brain glioma transplanted tumor is a BABL / c nude mouse subcutaneous transplanted tumor.
[0032] The radionuclide labeled molecular probe provided by the present invention (specifically 99m Compared with the prior art, TcO-DTPA-HSV) has the following beneficial effects:
[0033] 1) The present invention uses molecular docking technology to design and screen out targeting peptides that specifically bind to ANGPT2, filling the gap of high-affinity peptide ligands for ANGPT2;
[0034] 2) The radionuclide-labeled molecular probe prepared by the present invention is used as an imaging drug for brain glioma, and has the characteristics of long imaging time and easy preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 It is the structural formula of the polypeptide HSV in Example 1 of the present invention.
[0036] Figure 2 The HPLC and MS identification results of the HSV polypeptide prepared in Example 1 of the present invention are shown.
[0037] Figure 3 This is the three-dimensional docking model of the HSV polypeptide and the ANGPT2 protein in Example 1 of the present invention.
[0038] Figure 4 This is the affinity test result of HSV and ANGPT2 protein in Example 2 of the present invention.
[0039] Figure 5 It is the structural formula of FITC-HSV in Example 3 of the present invention.
[0040] Figure 6 The HPLC and MS identification results of FITC-HSV prepared in Example 3 of the present invention are shown.
[0041] Figure 7 The flow cytometer in Example 3 of the present invention compares the uptake of HSV by U87-MG cells (co-culture).
[0042] Figure 8 is the structural formula of DTPA-HSV prepared in Example 4 of the present invention.
[0043] Fig. 9 These are the HPLC and MS identification results of DTPA-HSV prepared in Example 4 of the present invention.
[0044] Fig.10 Prepared by Example 4 of the present invention 99m TLC detection results of TcO-DTPA-HSV.
[0045] Fig.11 Prepared by Example 4 of the present invention 99m In vitro stability experimental results of TcO-DTPA-HSV.
[0046] Fig.12 The U87-MG cell pair in Example 4 of the present invention 99m TcO-DTPA-HSV uptake results. *p﹤0.05, **p﹤0.01.
[0047] Fig.13 The BABL / c nude mice inoculated with U87-MG cells in Example 5 of the present invention were injected into the tumor 99m TcO-DTPA-HSV and 99m SPECT / CT imaging results of TcO. DETAILED DESCRIPTION
[0048] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0049] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0050] Example 1. Synthesis of HSV polypeptide
[0051] Artificially synthesized HSV, whose sequence is histidine-serine-valine-proline-arginine-histidine-glutamic acid-valine, His-Ser-Val-Pro-Arg-His-Glu-Val, abbreviated as HSVPRHEV, abbreviated as HSV, the structural formula is shown in Figure 1 ;
[0052] Select Fmoc-His(Boc)-Wang Resin with a substitution degree of 0.35mmol / g, and remove the Fmoc protecting group after swelling. According to the polypeptide sequence, coupling is carried out from the C-terminus to the N-terminus until His, and a small sample is taken for cutting to determine the correctness of the polypeptide. The side chain protecting groups of Ser, His, Arg, and Glu are tBu, Boc, pbf, and OtBu, respectively; all amino acids are protected by Fmoc at the α-position amino group. The lysis solution (volume ratio of trifluoroacetic acid: ethanedithiol: phenol: triisopropylsilane: water = 90:4:2:2:2) is reacted with the linear peptide resin to obtain a linear peptide with all side chain protecting groups removed. The linear peptide is dissolved in water and purified by semi-preparative chromatography to separate the liquid with qualified purity. The target polypeptide is collected after rotary evaporation and freeze-drying. The HPLC and MS identification results of HSV are shown in Figure 2 ;
[0053] The results of its interaction position with ANGPT2 are shown in Figure 3 The 5th Arg of the polypeptide forms a hydrogen bond with the 433rd Cys of ANGPT2, the 3rd Val of the polypeptide forms a hydrogen bond with the 450th Cys of ANGPT2, the 1st His of the polypeptide forms a hydrophobic binding interaction with the 475th Tyr of ANGPT2, and the 1st His of the polypeptide forms a hydrogen bond with the 476th Tyr of ANGPT2.
[0054] Example 2: Affinity identification of HSV and ANGPT2 proteins
[0055] ANGPT2 protein was diluted to 20 μg / mL with PBS for chip solidification, and the peptide was diluted to 100 μM with PBST (pH 7.4). The ANGPT2 protein solution was added dropwise to the NTA chip, and 200 μL of PBST (pH 7.4) was added to different wells of the solidified NTA chip as a control, and 200 μL of 100 μM peptide was added to the other wells. 250 μL of PBS buffer (pH 7.4) was injected into the sensor, and the buffer was run at the maximum flow rate (150 μL / min) to reach the signal baseline, and the flow rate of the buffer was reduced to 20 μL / min to obtain a more stable baseline. The signal of HSV binding to ANGPT2 protein is shown in Figure 2. Figure 4The results showed that HSV and ANGPT2 proteins had a strong binding interaction, and the equilibrium dissociation constant KD of the interaction between the two was 50.2nM.
[0056] Example 3: Analysis of HSV uptake by U87-MG cells
[0057] 1) FITC-HSV preparation
[0058] Synthesis steps: Select Fmoc-His(Boc)-Wang Resin with a substitution degree of 0.35mmol / g, and remove the Fmoc protecting group after swelling. According to the peptide sequence, coupling is carried out from the C-terminus to the N-terminus until His, and a small sample is cut to determine the correctness of the peptide; the side chain protecting groups of Ser, His, Arg, and Glu are tBu, Boc, pbf, and OtBu respectively; all amino acids are protected by Fmoc at the α position amino group. After confirming that the mass spectrum of the fragment peptide Fmoc-HSVPRHEV is correct, remove the Fmoc protecting group, add FITC with a molar multiple of 3 times, and react. The reaction is terminated after the ninhydrin test is negative. The linear peptide with all side chain protecting groups removed is obtained by reacting with the cleavage solution (volume ratio of trifluoroacetic acid: ethanedithiol: phenol: triisopropylsilane: water = 90:4:2:2:2) with the linear peptide resin. Dissolve the linear peptide in water, purify it using semi-preparative chromatography, separate the liquid with qualified purity, collect it and freeze-dry it to obtain FITC-HSV. The structural formula of FITC-HSV is shown in Figure 5 , HPLC and MS identification results are shown in Figure 6 .
[0059] 2) Quantitative and qualitative analysis of HSV uptake by U87-MG cells
[0060] bEnd.3 and HUVEC were plated in the upper and lower chambers of Transwell at a ratio of 1:5 with U87-MG cells, and cultured for 48 hours to simulate the blood-brain barrier and blood-brain tumor barrier. The culture medium of bEnd.3 and HUVEC cells in the upper chamber of Transwell was aspirated, and FITC-HSV and FITC with a final concentration of 20 μg / mL containing 10% FBS were added and incubated at 37°C. The U87-MG cells in the lower chamber were digested with 0.25% trypsin at 4 and 8 hours, respectively, and washed 3 times with cold PBS, and then resuspended in 300 μL cold PBS for flow cytometry to measure the cell fluorescence intensity. FITC without peptide was used as a control. The results showed that the FITC fluorescence intensity of U87-MG cells at 8 hours was greater than that of the 4-hour and FITC groups, indicating that HSV can be taken up by U87-MG cells ( Figure 7 ).
[0061] Embodiment 4, 99mPreparation of TcO-DTPA-HSV molecular probe
[0062] 1) Preparation of DTPA-HSV
[0063] Select Fmoc-His(Boc)-Wang Resin with a substitution degree of 0.35mmol / g, and remove the Fmoc protecting group after swelling. According to the peptide sequence, coupling is carried out from C-terminus to N-terminus until His, and a small sample is cut to determine the correctness of the peptide; the side chain protecting groups of Ser, His, Arg, and Glu are tBu, Boc, pbf, and OtBu respectively; all amino acids are protected by Fmoc at the α position amino group. After confirming that the mass spectrum of the fragment peptide Fmoc-HSVPRHEV is correct, remove the Fmoc protecting group, add DTPA-tetra (t-Bu ester) with a molar multiple of 3 times, and react. The reaction is terminated after the ninhydrin test is negative. The linear peptide with all side chain protecting groups removed is obtained by reacting with the cleavage solution (volume ratio of trifluoroacetic acid: ethanedithiol: phenol: triisopropylsilane: water = 90:4:2:2:2) with the linear peptide resin. Dissolve the linear peptide in water, purify it using semi-preparative chromatography, separate the liquid with qualified purity, collect it and freeze-dry it to obtain DTPA-HSV. The structural formula of DTPA-HSV is shown in Figure 8 , HPLC and MS identification results are shown in Fig. 9 .
[0064] 2) 99m TcO-labeled DTPA-HSV
[0065] 99m TcO-DTPA-HSV radioactive molecular probe includes DTPA-HSV and radionuclides 99m TcO, the HSV and 99m TcO is connected with DTPA, and its preparation method comprises the following steps:
[0066] (1) 99m TcO elution
[0067] Use a 5mL syringe to draw 5mL of normal saline to elute the molybdenum-technetium generator, collect the eluent into a centrifuge tube, and use a medical activity meter to detect the radioactivity, the activity is 5mCi.
[0068] (2) 99m TcO-labeled DTPA-HSV
[0069] DTPA-HSV was dissolved in ultrapure water to a final concentration of 1 mg / mL. 300 μL of DTPA-HSV solution was mixed with 100 μL of 1 mg / mL stannous chloride solution in 500 μL of PBS and 2.5 mCi 99mTcO was prepared by reacting at room temperature for 30 min. 99m Tc-DTPA-HSV radioactive molecular probe. The radiochemical purity of the radioactive molecular probe was tested using TLC, such as Fig.10 As shown, the radiochemical purity was 100%.
[0070] 3) 99m In vitro stability experiment of TcO-DTPA-HSV
[0071] The prepared radioactive molecular probe tracer (100 μL, 100 μCi) was placed in 1 mL of 10% fetal bovine serum and incubated at 37°C for 0.5, 1, 2, 4, 6 and 8 hours, and the radiochemical purity of the radioactive molecular probe was detected by TLC. Fig.11 As shown, the radioactive molecular probe has high stability in 10% fetal bovine serum, and the radiochemical purity is 100% 6 hours after labeling.
[0072] 4) 99m Cellular uptake experiment of TcO-DTPA-HSV
[0073] U87-MG cells were inoculated into 6-well plates and incubated for 24 hours. 99m TcO-DTPA-HSV (about 25 μCi) was added to 6-well plates, and free 99m TcO was added to a 6-well plate. After incubation for 1, 2, and 4 hours, the cells were washed three times with cold PBS, and then lysed with 0.5 mL of 1 M NaOH and counted using a gamma counter Wizard 2470. Uptake rate = gamma count of cells / 25 μCi 99m The gamma count of TcO × 100%. The results show that free 99m The cellular uptake in the TcO control group did not increase significantly over time, but 99m The cellular uptake in the TcO-DTPA-HSV group gradually increased over time, indicating that 99m TcO-DTPA-HSV has a targeted binding effect on U87-MG ( Fig.12 ).
[0074] Example 5: In vivo imaging of U87-MG cell transplanted tumors
[0075] 1) Establishment of U87-MG cell subcutaneous tumor animal model
[0076] U87-MG-luc cells in the logarithmic growth phase were obtained and digested with 0.25% trypsin to adjust the cell density to 1×10 5 / mL, and 5 μL of cell suspension was inoculated into the axilla of the right forelimb of the mouse.
[0077] 2) SPET / CT imaging of nude mice
[0078] U87-MG cell subcutaneous transplanted tumor nude mice 99m TcO group and 99m TcO-DTPA-HSV group, 99m The TcO group was injected with 200 μCi of 99m TcO, 99m The TcO-DTPA-HSV group was injected with 200 μCi of 99m TcO-DTPA-HSV, SPET / CT images were collected at 5min, 0.5h, 1h, 2h and 3h after administration. The results showed that 99m In the TcO group, the tumor was visualized 5 minutes after administration, but at 1, 2, and 3 hours, 99m TcO gradually spreads throughout the body, indicating that free 99m TcO has no targeted effect and circulates throughout the body with the blood; 99m In the TcO-DTPA-HSV group, images were only seen at the tumor site at 5 min, 0.5 h, 1 h, 2 h, and 3 h, and as time went by, 99m TcO-DTPA-HSV hardly diffused, indicating that the targeted binding of HSV to gliomas enabled the radioactive molecular probe to continuously image gliomas ( Fig.13 ).
[0079] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. A polypeptide targeting AGNPT2 protein, whose amino acid sequence is as follows: HSVPRHEV, His-Ser-Val-Pro-Arg-Histidine-Glu-Val, abbreviated as HSV.
2. Use of the polypeptide targeting AGNPT2 protein according to claim 1 in the preparation of a drug for diagnosing brain glioma.
3. Radionuclide labeled molecular probe, consisting of the following components: The polypeptide HSV targeting AGNPT2 protein, the chelating agent DTPA and the radionuclide in claim 1 99m TcO, in which the peptide HSV targeting the AGNPT2 protein is covalently coupled to the chelator DTPA, a radionuclide 99m TcO is chelated to the chelating agent DTPA.
4. The radionuclide-labeled molecular probe according to claim 3, characterized in that: The structural formula of the chelating agent DTPA is as follows: DTPA.
5. A method for preparing the radionuclide-labeled molecular probe according to claim 3 or 4, comprising the following steps: 1) Preparation of Chelating Agent-Peptide The polypeptide HSV is reacted with DTPA-tetra (t-Bu ester) to obtain the chelating agent-polypeptide DTPA-HSV; 2) Preparation of radionuclide labeled chelator-peptide Add radioactive nuclide to the mixed solution of chelating agent-peptide DTPA-HSV, stannous chloride and buffer 99m TcO, the reaction obtains a radionuclide labeled chelator-peptide, i.e., a radionuclide labeled molecular probe 99m TcO-DTPA-HSV.
6. The method according to claim 5, characterized in that: In step 1), the molar ratio of polypeptide HSV to DTPA-tetra (t-Buester) is 1:2-3.
7. The method according to claim 5 or 6, characterized in that: In step 2), the buffer is 0.1 M PBS buffer or physiological saline, pH 7.4, The chelating agent-polypeptide DTPA-HSV and stannous chloride, radionuclide 99m The ratio of TcO is: 0.1 mg- 0.3 mg: 0.1 mg: 2.5 mCi; The reaction temperature is room temperature and the reaction time is 15-30 min.
8. Use of the radionuclide-labeled molecular probe according to claim 3 or 4 in the preparation of a diagnostic reagent for brain glioma.
9. The use according to claim 8, characterized in that: In the application, the brain glioma is glioblastoma multiforme.
10. The use according to claim 8, characterized in that: The diagnostic reagent is used for imaging human brain glioma cells and brain glioma transplanted tumors in vivo.
